Quotient Limited to Participate in Upcoming Investor Conferences
Quotient Limited (NASDAQ:QTNT), a diagnostics firm, will participate in two investor conferences in June 2021. The Jefferies Virtual Healthcare Conference is scheduled for June 2, 2021, at 9:00am ET, while the Goldman Sachs 42nd Annual Global Healthcare Conference will take place on June 9, 2021, at 8:00am ET. Both presentations will be available via webcast on the company’s investor relations page, with replays archived for 90 days. Quotient is known for its MosaiQ technology, enhancing diagnostic efficiency, including its COVID-19 Antibody Microarray, which is CE marked and FDA authorized.
- None.
- None.
JERSEY, Channel Islands, May 31, 2021 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the management team will participate in two upcoming investor conferences.
Jefferies Virtual Healthcare Conference
Date: Wednesday, June 2, 2021
Presentation Time: 9:00am ET
Goldman Sachs 42nd Annual Global Healthcare Conference
Date: Wednesday, June 9, 2021
Presentation Time: 8:00am ET
A webcast of both presentations will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. Webcast replays will be archived on the website for approximately 90 days.
About Quotient Limited
Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that reshape the way diagnostics is practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and operational cost savings to laboratories around the world. In response to the global effort to combat COVID-19, Quotient developed the MosaiQ COVID-19 Antibody Microarray which is CE marked and has received the U.S. FDA Emergency Use Authorization. Quotient's operations are based in Eysins, Switzerland, Edinburgh, Scotland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
Contact: Peter Buhler, Chief Financial Officer, IR@quotientbd.com; +41 22 545 52 26
FAQ
What is the date of the Jefferies Virtual Healthcare Conference for Quotient Limited?
When will Quotient Limited present at the Goldman Sachs Healthcare Conference?
How can I watch the presentations by Quotient Limited at the investor conferences?
What technology does Quotient Limited use for diagnostics?
Is Quotient Limited's COVID-19 Antibody Microarray authorized for use?
